{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:58:32Z","timestamp":1792587512749,"version":"4.5.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Mucorale<\/jats:italic>\n                      has come into a significant pathogen over recent decades. Nonetheless, mucormycosis-related mortality rates among patients with hematological disorders remain unascertained. Thus, we conducted a meta-analysis to determine mortality rates of mucormycosis in patients with hematology-related conditions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We scoured PubMed, Embase, and Web of Science for original papers exploring the intersection of Mucormycosis and Hematological Diseases (from 2000 to 2022). We scrutinized the overall mortality across three distinct periods, as well as differentiating between high-income and middle-income nations. We further evaluated the pooled mortality and the risk differential (RD) across several subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall mortality rate for hematology patients with mucormycosis was 61%, within a 95% confidence interval (CI) of 0.54\u20130.68. A significant observation was that mortality rates were somewhat lower in high-income countries compared to middle-income countries (0.60 versus 0.64,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.45). Importantly, we discovered that a combination of surgical and medical treatment significantly improved survival rates compared to medical treatment alone [mortality 0.49 versus 0.67, RD -0.19 (95%CI -0.38-0.00, I\n                      <jats:sup>2<\/jats:sup>\n                      63.7%)]. As might be expected, disseminated mucormycosis posed a significantly higher risk of death compared to isolated mucormycosis [0.60 versus 0.57, RD death 0.16 (95%CI 0.03\u20130.28)]. Additionally, our analysis showed no discernible differences in survival rates between genders, between patients with and without breakthrough infection, between those who received mucor-active or mucor-inactive drugs prior to mucor infection, or between those on a multi-drug regimen and those on a single drug treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the high mortality rates associated with mucormycosis in patients with hematological disorders, those receiving both medical and surgical interventions, as well as those with isolated infection sites, exhibited improved survival outcomes. Conversely, factors such as gender, the presence of breakthrough infection, the use of mucor-active drugs before mucor infection, and multi-drug administration did not significantly influence patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2023.1268840","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T02:17:45Z","timestamp":1701310665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["The outcome and the risk factors of mucormycosis among patients with hematological diseases: a systematic and meta-analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Meixiao","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/jof6040265","article-title":"Epidemiology and diagnosis of Mucormycosis: an update","volume":"6","author":"Skiada","year":"2020","journal-title":"J Fungi"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1128\/CMR.13.2.236","article-title":"Zygomycetes in human disease","volume":"13","author":"Ribes","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/mmy\/myy060","article-title":"A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment","volume":"57","author":"Prakash","year":"2019","journal-title":"Med Mycol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1093\/cid\/cir880","article-title":"French mycosis study G: a global analysis of Mucormycosis in France: the RetroZygo study (2005-2007)","volume":"54","author":"Lanternier","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11046-021-00607-4","article-title":"Mucormycosis in mainland China: a systematic review of case reports","volume":"187","author":"Wei","year":"2022","journal-title":"Mycopathologia"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/13693780500464930","article-title":"The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus","volume":"44","author":"Chakrabarti","year":"2006","journal-title":"Med Mycol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/jof7110985","article-title":"Global prevalence of COVID-19-associated Mucormycosis (CAM): living systematic review and Meta-analysis","volume":"7","author":"Hussain","year":"2021","journal-title":"J Fungi"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/jof7080616","article-title":"Connecting the dots: interplay of pathogenic mechanisms between COVID-19 disease and Mucormycosis","volume":"7","author":"Prakash","year":"2021","journal-title":"J Fungi"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/jof5010026","article-title":"Global epidemiology of Mucormycosis","volume":"5","author":"Prakash","year":"2019","journal-title":"J Fungi"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","article-title":"The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports","volume":"25","author":"Jeong","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e1380","DOI":"10.1093\/cid\/ciab386","article-title":"Isavuconazole treatment of invasive fungal sinusitis: a post hoc analysis of the SECURE and VITAL trials","volume":"73","author":"Durand","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/IDR.S102207","article-title":"Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations","volume":"9","author":"Natesan","year":"2016","journal-title":"Infect Drug Resist"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Mycoses study group E, research C, the European Confederation of Medical M: defining breakthrough invasive fungal infection-position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"ref17","volume-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2020"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ijantimicag.2019.01.002","article-title":"Contemporary management and clinical outcomes of mucormycosis: a systematic review and meta-analysis of case reports","volume":"53","author":"Jeong","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the mycoses study group education and research consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1182\/blood-2011-03-316430","article-title":"How I treat mucormycosis","volume":"118","author":"Kontoyiannis","year":"2011","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/myc.12149","article-title":"Prospective antifungal therapy (PATH) alliance((R)): focus on mucormycosis","volume":"57","author":"Kontoyiannis","year":"2014","journal-title":"Mycoses"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.cmi.2020.12.035","article-title":"Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis","volume":"27","author":"Muthu","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13613-020-00673-9","article-title":"Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy","volume":"10","author":"Claustre","year":"2020","journal-title":"Ann Intensive Care"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13613-021-00818-4","article-title":"Poor outcome associated with mucormycosis in critically ill hematological patients: results of a multicenter study","volume":"11","author":"Jestin","year":"2021","journal-title":"Ann Intensive Care"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/archinte.159.12.1301","article-title":"Pulmonary mucormycosis: the last 30 years","volume":"159","author":"Lee","year":"1999","journal-title":"Arch Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/10428190310001653691","article-title":"Improved outcome of zygomycosis in patients with hematological diseases?","volume":"45","author":"Gleissner","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/0003-4975(94)90243-7","article-title":"Pulmonary mucormycosis: results of medical and surgical therapy","volume":"57","author":"Tedder","year":"1994","journal-title":"Ann Thorac Surg"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"811.e1","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijid.2022.04.009","article-title":"Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series","volume":"120","author":"Soman","year":"2022","journal-title":"Int J Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/myc.12247","article-title":"Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia","author":"Klimko","year":"2014","journal-title":"Mycoses"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"108731","DOI":"10.1016\/j.clim.2021.108731","article-title":"Invasive fungal disease and the immunocompromised host including allogeneic hematopoietic cell transplant recipients: improved understanding and new strategic approach with sargramostim","volume":"228","author":"Chu","year":"2021","journal-title":"Clin Immunol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J Infect Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole","volume":"40","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jinf.2023.05.005","article-title":"Breakthrough invasive fungal infection among patients with haematologic malignancies: a national, prospective, and multicentre study","volume":"87","author":"Puerta-Alcalde","year":"2023","journal-title":"J Infect"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"myad046","DOI":"10.1093\/mmy\/myad046","article-title":"Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: clinical features, risk factors, and posaconazole profiles","volume":"61","author":"Hong","year":"2023","journal-title":"Med Mycol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1128\/CMR.18.3.556-569.2005","article-title":"Novel perspectives on mucormycosis: pathophysiology, presentation, and management","volume":"18","author":"Spellberg","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1089196","DOI":"10.3389\/fcimb.2023.1089196","article-title":"Mucor indicus caused disseminated infection diagnosed by metagenomic next-generation sequencing in an acute myeloid leukemia patient: a case report","volume":"13","author":"Shen","year":"2023","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1268840\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T02:17:55Z","timestamp":1701310675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1268840\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":39,"alternative-id":["10.3389\/fmed.2023.1268840"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1268840","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"article-number":"1268840"}}